QQQ $ 455.25 $ 5.77 (1.29 %)
DIA $ 409.08 $ 4.58 (1.13 %)
SPY $ 546.60 $ 6.05 (1.12 %)
TLT $ 99.96 $ 0.43 (0.43 %)
GLD $ 231.58 $ 0.97 (0.42 %)
$ 31.68
-- x --
-- x --
-- - --
$ 26.91 - $ 54.94
372
na
nm
$ 0.62
nm
TBD
na
na (nm)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bayer-weedkiller-lawsuit-dismissed-by-australian-judge-insufficient-evidence-linking-roundup-to-blood-cancer

Australian judge dismisses class action lawsuit against Bayer for Roundup causing cancer. Ruling supports company's stance ...

 judge-slashes-bayers-massive-2b-roundup-verdict-to-400m

Pennsylvania judge cuts Bayer's $2.25 billion Roundup verdict to $400 million. Both Bayer and plaintiff plan appeals in the...

 after-unitedhealth-cyberattack-drug-distributor-cencora-notifies-americans-health-information-stolen-in-data-breach-in-february

Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnose...

 bayer-highlights-detailed-data-from-twin-late-stage-trials-on-experimental-menopause-candidate-seeks-regulatory-approval

Bayer to present detailed Phase 3 OASIS 1 and 2 study results showing elinzanetant significantly reduces moderate to severe men...

 bayers-monsanto-scores-legal-victory-as-185m-verdict-overturned

Bayer's Monsanto unit secures a significant legal victory as Washington state appeals court overturns $185 million verdict ...

 bayers-third-menopausal-relief-drug-trial-meets-primary-goal-german-conglomerate-seeks-fda-approval-for-elinzanetant

Bayer's Phase 3 study OASIS 3 findings on elinzanetant, a promising non-hormonal treatment for menopausal hot flashes. Resu...

 german-conglomerate-bayer-goes-johnson--johnson-way-to-tackle-its-cancer-related-lawsuits

Bayer contemplates Texas Two-Step bankruptcy to tackle Roundup lawsuits in the US amid mounting jury verdicts. Learn about the ...

 bayer-holds-splitting-into-separate-units-for-three-years-focus-shifts-on-tackling-challenges

Bayer charts strategic course amid structural evaluation. CEO Bill Anderson addresses group's challenges, prioritizing perf...

 whats-going-on-with-bridgebio-pharma-stock-on-monday

BridgeBio Pharma partners with Bayer on acoramidis for ATTR-CM in Europe. $310 million deal, FDA application accepted.

 weedkiller-woes-australian-court-nears-decision-in-bayers-roundup-trial

Follow the landmark Australian Roundup lawsuit against Bayer. Closing arguments in class action alleging Roundup's link to ...

 roundup-cancer-verdict-woes-continue-for-bayer-as-it-faces-22b-payout

"Bayer's Monsanto ordered to pay $2.2 billion in Roundup cancer case. Explore the landmark verdict, compensatory losses...

 large-drugmakers-show-enthusiasm-to-embrace-100b-obesity-market-despite-novo-and-lillys-dominance

Pharmaceutical companies, including Amgen Inc (NASDAQ: AMGN) and Pfizer Inc (NYSE: PFE), are strategically positioning themselv...

 menopause-management-bayers-non-hormonal-treatment-option-shows-efficacy-in-trial

Monday, Bayer AG (OTC: BAYRY (OTC: BAYZF) 

 bayer-study-on-parkinsons-disease-gene-therapy-succeeds-in-early-stage-trial

Bayer completed an 18-month data collection in the Phase Ib trial for a gene therapy for treating patients with Parkinson's.

 legal-victory-for-bayer-roundup-lawsuit-ends-five-trial-losing-streak

In a significant turn of events, Bayer AG (OTC: BAYRY) (OTC: BAYZF) emerged victorious in a California lawsuit filed by Bruce J...

 esg-stocks-take-center-stage-as-damages-from-climate-related-events-rise-exponentially-within-us

With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer A...

 bayer-faces-35m-verdict-in-fifth-consecutive-roundup-weedkiller-loss

Bayer AG (OTC: BAYRY) (OTC: 

 bayer-faces-growing-pressure-amid-roundup-lawsuits-as-philadelphia-trial-nears-conclusion

The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surround...

 german-conglomerate-bayer-faces-investor-scrutiny-amid-unexpected-legal-trial-setbacks

Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors f...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION